Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: A multicenter, retrospective analysis

Clinical Colorectal Cancer

Volumn 9, Issue 5, 2010, Pages 305-310

  Nishiofuku, Hideyuki ^a   Tanaka, Toshihiro ^a   Aramaki, Takeshi ^a   Boku, Narikazu ^a   Inaba, Yoshitaka ^a   Sato, Yozo ^a   Matsuoka, Masaki ^a   Otsuji, Toshio ^a   Arai, Yasuaki ^a   Kichikawa, Kimihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

5 FU; Alkaline phosphatase; Prognostic factor; Third line chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE CONTROL; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; INTRAARTERIAL DRUG ADMINISTRATION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 78651098415     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.044     Document Type: Article

References (28)

1. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
2. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of xuorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14.
3. Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19:1141-5.
4. Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. Br J Cancer 2006; 94:792-7.
5. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1999; 49:8-31.
6. Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol 2007; 25:5649-54.
7. Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-54.
8. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: A multicentre randomised trial. Lancet 2003; 361:368-73.
9. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer. A randomized trial of efficacy, quality of life, and molecular markers (CALGB9481). J Clin Oncol 2006; 24:1395-403.
10. Arai Y, Takeuchi Y, Inaba Y, et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interventional Rad 2007; 10:30-7.
11. Inaba Y, Arai Y, Matsueda K, et al. Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2001; 12:957-63.
12. Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2003; 14:63-8.
13. Arai Y, Inaba Y, Takeuchi Y, et al. Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 1997; 40:526-30.
14. Meyerhardt J, Mayer R. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87.
15. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-9.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
18. Ardavanis AS, Ioannidis GN, Orphanos GS, et al. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 2006; 26:1669-72.
19. Lim DH, Park YS, Park BB, et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: A phase II study. Cancer Chemother Pharmacol 2005; 56:10-4.
20. Yasui H, Yoshino T, Boku N, et al. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and Irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol 2009; 39:315-20.
21. Gundgaard MG, Soerensen JB, Ehrnrooth E. Third-line for metastatic colorectal cancer. Cancer Chemother Pharmacol 2008; 61:1-13.
22. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8.
23. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracilbased treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-17.
24. Diaz R, Aparicio J, Girones R, et al. Analysis of prognostic factors and applicability of Köhne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005; 5:197-202.
25. Kemeny NE, Huitzil Melendez FD, Capanu M, et al. Conversion to respectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27:3465-71.
26. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19:2687-95.
27. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888-96.
28. Gallagher DJ, Capanu M, Raggio G, et al. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis. Ann Oncol 2007; 18:1995-9.